Neurana Pharmaceuticals, Inc.

Neurana Pharmaceuticals, Inc. is focused on developing innovative pharmaceutical treatments for neurological disorders, aiming to meet critical unmet medical needs with advanced therapies and research. Neurana Pharmaceuticals, Inc. was founded in 2013 and is headquartered in San Diego, US.

The company specializes in developing pharmaceutical solutions for neurological conditions. In May 2018, Neurana secured a Series A funding round of USD 60 mn, led by Sofinnova Investments, with participation from H. I. G.

BioHealth Partners, Longitude Capital, MagnaSci Ventures, and New Leaf Venture Partners. The total amount raised to date is USD 60 mn. The current CEO is Craig Thompson, who has a background in leading pharmaceutical ventures. Neurana Pharmaceuticals specializes in developing innovative pharmaceutical solutions aimed at addressing critical unmet medical needs, particularly for neurological disorders.

Their product offerings target conditions such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, providing both symptomatic relief and potential disease-modifying effects. Neurana's development process includes preclinical and clinical trials to ensure safety and efficacy prior to market release. Their customer base comprises healthcare providers, hospitals, and specialty pharmacies, primarily serving markets in North America and Europe. Neurana Pharmaceuticals generates revenue through direct sales to healthcare facilities and pharmaceutical distributors, primarily for prescription medications often covered by insurance.

The company engages in strategic collaborations with larger pharmaceutical firms to enhance distribution channels. Pricing is determined based on market dynamics and therapeutic value to maintain competitiveness while delivering high-quality solutions. Their flagship products cater to chronic neurological conditions and are positioned as premium offerings for effective treatment options. With the recent Series A funding of USD 60 mn secured in May 2018, Neurana Pharmaceuticals plans to expand its product portfolio with new treatments aimed at neurological disorders, although specific launch dates have not been disclosed.

The company aims to enter new markets in Europe and Asia by 2025 to enhance patient access to its therapies. The funding will be utilized to support ongoing clinical trials and expedite the development of new products, thereby strengthening their market presence.